India and Russia pharma ties deepen as Putin calls for boost in Indian drug imports
In a strategic move to rebalance trade with India, Russian President Vladimir Putin has directed his government to ramp up imports of Indian pharmaceuticals and agricultural products.
With pharmaceuticals already representing a $5 billion surplus in India’s favor, the Kremlin’s push signals a major opportunity for Indian drugmakers to expand their footprint in Russia’s pharmaceutical market, reports The Pharma Letter’s India correspondent.
The announcement coincides with a high-level bilateral meeting held in India late last month between JP Nadda, Health Minister and Dmitry Nikolaevich Patrushev, Deputy Prime Minister of the Russian Federation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze